Monitoring multidrug-resistant organisms (MDROs) and the infections they cause in a healthcare setting is important to detect newly emerging antimicrobial resistance profiles, to identify vulnerable patient populations, and to assess the need for and effectiveness of interventions; however, it is unclear which metrics are the best, because most of the metrics are not standardized. This document describes useful and prac tical metrics and surveillance considerations for measuring MDROs and the infections they cause in the practice of in fection prevention and control in healthcare settings. These metrics are designed to aid healthcare workers in docu menting trends over time within their facility and should not be used for interfacility comparison.
INTRODUCTION
Multidrug-resistant organisms (MDROs) are microorganisms that are resistant to one or more therapeutic classes of an timicrobial agents. I Healthcare facilities are monitoring MDROs in a variety of ways because of the increasing inci dence of MDRO infections, the severity of infection caused by MDROs, changes in reporting requirements, and rec ommendations by the Healthcare Infection Control Practices Advisory Committee (HICPAC). 
Definitions Used for Epidemiologic Classification of Infections With Multidrug-Resistant Organisms (MDROs)
Classification Definition
Te mporal Hospital-onset Specimen was collected from patient after defined time period of hospitalization to best reflect that the pathogens were acquired in the hospital. Recommended definition is based on specimens being col lected >3 calendar days after patient was admitted to the hospital (first day is date of admission). This is known as the "3 midnight rule." For example, if a patient is admitted to the hospital at any time on a Monday, only MDROs that are isolated after midnight Wednesday night would be consid ered to represent hospital-onset infection (ie, specimen was collected on day 4 of hospitalization). All hospital-onset infections are considered healthcare-associated. Community onset Specimen was collected before defined time period of hospitalization to best reflect that the pathogens were acquired either in the community (including other institutions or homes) or during a previous hospitalization. Recommended definition is based on specimens being collected ,i;:;; 3 calendar days after the patient was admitted to the hospital. A subset of community-onset infections may be healthcare-associated. Clinical
Healthcare-associated Categorization requires evaluation of the patient's clinical history, as well as the timing of specimen collection for clinical cultures. Patient has an identified association with recent healthcare delivery, such as current or recent hospitalization, use of an indwelling venous catheter, residence in a long term care or rehabilitation hospital, recent surgery, and/or receipt of outpatient dialysis. These types of exposure to healthcare settings may vary as a result of study design and availability of data. Therefore, if data are available, community-onset infections (see above) could be categorized as healthcare-associated, to better understand the role played by healthcare facilities in the potential transmission of MDROs. Nosocomial Categorization requires evaluation of the patient's clinical history, as well as the timing of specimen collection for clinical cultures. The infection in a patient was likely to have been acquired during the hospital stay, without any evidence that infection was incubating or present on admission. Community-associated Categorization requires the evaluation of the patient's clinical history, as well as the timing of specimen collection for clinical cultures. Patient has no documented healthcare-associated risk factors (ie, community-onset infection [see above] and there is no identified association between patient and recent healthcare delivery).
terventions.
1 However, it is unclear which metrics for mon itoring MDROs and the infections they cause are the best, because most metrics are not standardized.
The purpose of this document is to define reasonable and practical metrics and surveillance considerations for MDROs that will help detect changes in occurrence of MDRO colo nization or infection in response to interventions in health care settings. This document should be used as a guide for hospital epidemiologists and infection control professionals for choosing the metrics most appropriate and useful for their specific setting. These recommendations offer standardization and increase reliability in the utility of the metric for local prevention efforts; however, these metrics should not be used for interfacility comparison, because the best means of risk adjustment have not been identified. Therefore, these metrics should not be promoted for external reporting purposes until after appropriate validation studies have identified the best measures for such reporting. Process metrics, such as the percentage of healthcare facilities that adhere to active sur veillance testing (AST) or that comply with hand hygiene and contact precautions, are used by many facilities but are not addressed in this document, which focuses on outcome metrics.
The Centers for Disease Control and Prevention (CDC) and the Society for Healthcare Epidemiology of America (SHEA) convened a working group of experts to review the existing published and unpublished literature and guidelines on MDRO metrics and surveillance strategies. The working group consisted of experts from the CDC, SHEA, HICPAC, and the Association for Professionals in Infection Control and Epidemiology.
Issues to Consider When Using MDRO Surveillance Methods
Pathogens. The MDROs of greatest concern to healthcare facilities include (1) methicillin-resistant Staphylococcus au reus (MRSA), (2) vancomycin-resistant enterococci (VRE), 1 For some MDR gram-negative bacilli, such as car bapenem-resistant Enterobacter species and extended-spec trum ,6-lactamase-producing Klebsiella species, the specific drug resistance patterns cause concern because of the chal lenges they present in treatment and infection prevention. However, no standard definitions exist for multiple drug re sistance for many gram-negative bacilli. Percentage of strains of methicillin-resistant Staphylococ cus aureus (MRSA) isolated from clinical cultures at 3 hospitals in the first 5 days of hospitalization, by day after admission. Hospital I reported 1,865 isolates, hospital 2 reported 1,319 isolates, and hospital 3 reported 1,004 isolates. All isolates were nonduplicates (ie, the first isolate recovered from each patient during the reporting period). The percentages of isolates stabilized after day 3 for hospitals I and 3, and after day 2 for hospital 2. The percentages of isolates obtained after day 5 were 23% for hospital 1, 42% for hospital 2, and 12% for hospital 3 (data were supplied courtesy of Bala Hota, Cook County Bureau of Health Services, Chicago, IL).
should define MDR gram-negative bacilli on the basis of local scenarios, and the definition should be consistent over time to ensure valid longitudinal comparisons. For example, mul tidrug-resistant Pseudomonas aeruginosa may be considered to be isolates that are resistant to 3 or more classes of anti microbials ( eg, carbapenems, piperacillin, quinolones, and aminoglycosides), and extended-spectrum cephalosporin-re sistant Klebsiella pneumoniae may be considered to be isolates that are resistant to either ceftriaxone or ceftazidime. This document does not address Clostridium difficile, which is con sidered by some to be an MDRO and has been addressed elsewhere.
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Infection and colonization. MDROs might be associated with either symptomatic illness {ie, clinical disease or infec tion) or asymptomatic carriage (ie, colonization). Differen tiating colonization from infection can be difficult; clinical assessments for therapy and for surveillance of healthcare associated infections often require the accumulation of ad ditional evidence other than a positive microbiological test result. For example, cultures of respiratory-tract specimens that grow MDROs often reflect endotracheal colonization. Without substantial supporting evidence, culture-positive specimens may neither represent clinical infection nor fulfill the case definition of ventilator-associated pneumonia. Be cause many considerations are involved in identifying clinical infections, selecting metrics that minimize the need for clin ical interpretation can allow for more consistent and objective surveillance. [7] [8] For example, the recovery of pathogenic or ganisms from certain clinical specimens is almost universally associated with clinical infection; these specimens include blood 9 and samples from other normally sterile body sites, such as cerebrospinal fluid, pleural fluid, synovial or joint fluid, bone, pericardia! fluid, and peritoneal fluid. 10 In con trast, the isolation of MDROs from specimens of nonsterile body sites, which include sputum and wounds, does not nec essarily represent clinical disease.
Hospital-onset and community-onset infections. Infections identified in patients after 48-72 hours of hospitalization or 48-72 hours after hospital discharge are often defined as nos ocomial in the absence of evidence of active or incubating infection on admission. Nosocomial infections are also often termed "hospital-onset" and are only a subset of all health care-associated disease; "hospital-onset" is defined using only information related to the timing of specimen collection in relation to hospital admission. Hospital-onset categorization is easier to apply than categorization requiring clinical eval uation, but it is less specific for identifying true nosocomial infections, because the assessment of recent healthcare ex posures or of whether an infection may have been incubating at the time of admission is lacking (Table 1 ) . Healthcare associated disease encompasses hospital-onset infections and includes infections with disease onset in the community in persons with recent exposures to healthcare delivery.
11 For the routine categorization of MDRO infection, definitions for nosocomial MDRO infections would be useful for distin guishing MDRO infections associated with the current hos pital stay from MDRO infections associated with exposures unrelated to the current hospital stay. However, the need to apply clinical considerations (such as the incubation period, the presence of infection at the time of admission by review of symptoms, or recent hospital discharges) to the classifi cation of infection can be burdensome to apply facility wide.
One strategy for addressing this issue of classification of infection is to use proxy, laboratory-based MDRO metrics based on the timing of culture results relative to hospital admission. Specifically, we recommend that an MDRO be considered hospital-onset if the organism is isolated after the third calendar day of hospitalization, with the first day being the day of admission ( the admission date is determined as the date a patient occupies a room for an overnight stay, not the date of an outpatient and/or emergency department visit; Table 1 ). This recommendation is made for the following reasons: (1) a calendar-day definition is easier to apply than the 48-hour rule; (2) it reduces variability in application of the definition by infection prevention and control staff; and (3) it ensures that patients have been hospitalized for at least a full 48 hours. Few MDRO infections have known incubation periods, but a recent evaluation of 3 hospitals in the Chicago area found that most MRSA isolates were cultured from sam ples obtained within the first 3 days after admission, which suggests that most community-associated MRSA infections will be identified by hospital day 4 ( Figure) . This definition is to be distinguished from the definition of the National Healthcare Safety Network and from other nosocomial in fection definitions, which require chart review and bedside • A patient might be counted more than once during a surveillance period if the positive blood culture results are for specimens obtained at least 14 days apart; similarly, multiple isolates from the same patient should not be counted if they are obtained within 14 days of the first positive culture result, even if it spans 2 surveillance periods.
b Prevalence density and incidence density differ from prevalence rate and incidence rate in their denominators: for the prevalence or incidence density, the number of patient-days is used as the denominator; for the prevalence or incidence rate, the number of admissions to hospital is used as the denominator. ' Definitions are from the Centers of Disease Control and Prevention's National Healthcare Safety Network.'
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• For example, patients with ventilator-associated pneumonia due to multidrug-resistant gram-negative bacilli.
• For example, patients with methicillin-resistant Staphyloccus aureus surgical site infection. r A subset of admission-prevalent MORO isolates may be attributable to patients who were previously hospitalized or who visited an outpatient clinic, but the degree of variability in accessing these data and the lack of a standard definition to apply limit our recommendation of the admission prevalence rate as defined here. HCFs may clioose to further categorize isolates on the basis of patient exposure to the HCP, as outlined in Table 1 , to attribute colonization or infection to prior hospital exposure.
• Healthcare acquisition of an MORO occurs in a patient without MORO colonization or infection on admission (because the patient either had no prior history of MORO colonization or infection, had no positive clinical or AST result during the first 3 days of hospitalization, or had not been tested during the first 3 days of hospitalization) who subsequently has either a positive AST result or clinical culture of a sample obtained � 3 calendar days after admission. Furthermore, using different types of AST techniques with varying sensitivities may affect the acquisition metrics (e.g., switching from polymerase chain reaction [PCR]-based AST to culture-based AST, or using PCR-based AST at admission and culture-based AST at discharge). Not applicable 100 patient admissions (prevalence); 1,000 patient-days (prevalence density)" 100 patient admissions (prevalence); 1,000 patient-days (prevalence density)" 100 patient admissions 100 patient admissions 100 patient admissions (incidence); 1,000 patient-days (incidence density)" 100 patient admissions (incidence); 1,000 patient-days (incidence density)" assessment to determine the presence of active or incubating infection. Without these clinical assessments, a temporal def inition of hospital-onset colonization or infection will result in a conservative underestimate of MDRO colonization or infection attributable to the hospital stay, but it is likely a more specific measure (fewer false positive findings) for as certainment of nosocomial MDRO colonization or infection.
Patients with a history of colonization or infection. Patients might be persistently colonized with an MDRO, and the du ration of colonization depends on the MDRO. MRSA can be carried in the nares for more than 1 year 12 ; in one study, sub sequent MRSA infections occurred in 29% of patients within 18 months of a previous colonization or infection. 13 Similarly, colonization with VRE and MDR gram-negative bacilli can also be prolonged, lasting for more than 1 year.
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To identify the prevalence or incidence of MDRO colo- nization or infection, knowing which patients have a history of colonization or infection ("historically positive") is im portant. A patient with a history of colonization or infection is one with a known positive clinical or surveillance test result (from the healthcare facility where the patient is being treated or from another healthcare facility where the patient could have received medical care) at the time he or she is being admitted to the new healthcare facility for treatment. We recommend that, once a patient has tested positive for MDRO colonization or infection at any healthcare facility, that patient should be considered to have this status indefinitely (ie, "once positive, always positive"). If the referring facilities lack the pertinent data, then we recommend that, at a minimum, the new facilities try to identify patients with a history of MDRO positivity by searching their own laboratory records for MDRO isolates from the year before admission. Please refer to CLSI document [37] .
Basic for all MDROs. For MDR grani-negative bacilli, specifically, this metric could be especially useful for monitoring its emergence. Useful for assessing the burden of a specific organism, regardless of extrinsic risk factors (e.g., catheter or ventilator use). Useful for assessing the burden of specific device-associated infections or specific populations ( e.g., orthopedic patients).
Reasonable initial risk assessment. This metric underestimates the hidden reservoir for MRSA [25] , VRE [24] , and MOR gram-negative bacilli. This metric could be especially useful for MRSA infection or colonization in an intensive care unit because it follows the same trends as overall preva lence based on clinical culture and AST data [25] . If coupled with point prevalence AST data, this metric allows an assessment of the degree to which clinical culture data alone underestimate the full reservoir. This metric will be especially useful for an HCF that wants to monitor patients that are affiliated with it; on the other hand, this metric will be more dif ficult to interpret for HCFs that share patient populations. Very useful for robust assessment of intervention if conducting AST." Useful adjunct metric if there is concern about importation from the com munity or another HCF.
Useful adjunct metric for HCFs not conducting routine AST. Helps provide an estimate of the degree to which clinical culture data underestimate the full reservoir. Could help guide HCFs to decide when to initiate AST in select populations or units. Very useful part of a risk assessment to define high-risk areas or populations of an H CF.
Useful for VRE and MDR grani-negative bacilli in certain circumstances only, such as during an outbreak or for monitoring emergence,.because it substantially underestimates the hidden reservoir [24] . MRSA colonization or infection is also substantially underestimated, but estimates will likely correlate with rates in which AST data are added. Provides a more accurate metric than incidence based on clinical culture data, if conducting routine AST.'
NOTE. AST, active surveillance testing; CLSI, Clinical and Laboratory Standards Institute; HCF, healthcare facility; MOR, multidrug-resistant; MRSA, methicillin-resistant S. aureus; VRE, vancomycin-resistant Enterococcus.
• All facilities should use the basic metrics in all circumstances. The context in which advanced metrics are recommended is noted in the comments. The use of the advanced metrics does not supplant the use of the basic ones. b This metric could be used in place of overall prevalence rate based on clinical culture data. ' This metric could be used in place of incidence rate based on clinical culture data.
Surveill a nce period. We recommend that MDRO data be reviewed regularly for trends and for assessment of response to specific interventions. In general, we recommend that as sessment of clinical cultures be performed monthly, with an appropriate calculation of both numerators and denomina tors. These values can later be used to calculate annual pooled rates of monthly calculations. For small facilities with only infrequent cases of MDRO colonization or infection, all met rics might need to be calculated quarterly or annually, to make them more meaningful. In an outbreak situation, daily or weekly calculations could be warranted.
Duplicate MDRO isol a tes from the same patient. Duplicate isolates can be defined operationally as all MDRO isolates recovered from specimens collected after initial isolation of the MORO from the same patient during the defined sur veillance period, regardless of specimen source. For most met rics, only the first MORO isolate recovered from a patient during a given surveillance period should be included, so that the rates of MORO colonization or infection are not over estimated.11-2 0 Although recurrent positive blood culture re sults can occur for the same patient after treatment, discrete episodes of bacteremia should be considered separate events. Recommendations for handling this specific situation (ie, re current positive blood culture results) are discussed below, in the subsection "Estimating Infection Burden."
Location and patient population. Surveillance may be con ducted throughout the healthcare facility or in specific areas, such as high-risk units (eg, intensive care units [ICU]), lo cations with a historically high prevalence of MORO colo nization or infection ( eg, specialty care areas, such as he matology and oncology wards, inpatient dialysis units, bum units, and long-term care areas), and units where interven tions are planned or occurring. In addition, facilities might want to monitor specific patient populations with character istics that place them at increased risk for acquiring MOROs. 1 · 21 · 22 Because this document is a guide for the use of metrics for evaluation of MOROs to inform local inter vention efforts, we recommend, at a minimum, that the met rics be used in hospital units planning or conducting inter ventions. For location-specific metrics, MORO colonization or infection should be attributed to the location of the patient at the time of specimen collection. Use of an additional hos pital-wide metric can allow one to evaluate the impact of MOROs outside of the intervention area. Stratification of the findings of some metrics by location can demonstrate dif ferences that are of clinical utility, such as with antibiograms, which demonstrate the higher prevalence of resistance to an timicrobials among MORO isolates recovered from ICUs pa tients, compared with those recovered from all other hospital patients. 23 Stratification of the findings of other proposed metrics has not been well studied to date.
Prevalence and incidence metrics. The prevalence rate of MORO infection or colonization is the total number of patients with MORO infection or colonization in a specific population during a specified period of time. An incidence rate of MORO infection or colonization is the total number of patients with newly acquired MORO infection or colonization in a specific population during a specified period. For most MORO metrics, we recommend calculating a simple prevalence or incidence per 100 patients admitted to the hospital, because it is easily understood and provides the same relative quantification as the metrics that use population density (ie, a denominator of patient-days). 2 4.25 If desired, calculating prevalence density or incidence density will better account for length of patient stay (ie, all days during which patients are at risk for MORO in fection or colonization). Prevalence density and incidence den sity differ from prevalence rate and incidence rate in their denominators: for the prevalence or incidence density, the number of patient-days is used as the denominator; for the prevalence or incidence rate, the number of admissions to the hospital is used as the denominator. A patient-day is the period between a census-taking hour or specific time of day and that same exact hour or time of day on the following calendar day (eg, midnight to midnight). We recommend that partial days be excluded from the total patient-day count unless the partial day is the day of admission. 26 For accuracy, the denominators for incidence metrics can be adjusted for the at-risk population; patients may not be considered "at risk" for MORO colonization or infection if they have been in the hospital for 3 or fewer calendar days, or if they have had prior colonization or infection, depending on the metric. Nevertheless, for simplicity, we recommend proxy measures in which all admitted patients or all patient days are included in the denominator rather than counting only those admitted patients or patient-days in which the patient is at risk for colonization or infection. The rationale for this recommendation is that, in general, identifying pa tients or patient-days at risk is time-consuming and not stan dard procedure; also, we do not know at this time whether using patients or patient-days at-risk will substantiallYaffect the interpretation of data trends at most facilities. Further more, patient-days attributed to patients colonized or infected with an MORO (ie, patient-days that would arguably be re moved from the denominator) still represent time the patient is at risk for acquiring a second strain of the same MORO. We recognize that including all patients in the denominator might artificially lower the incidence rate and that changes in length of stay over time may affect trends in a facility. This recommendation is best applied to hospitals with a low prev alence of MORO colonization or infection. Hospitals with short lengths of stay could disproportionately underestimate the incidence of MORO colonization or infection because fewer cases will be identified 3 days after admission.
AST. Given that colonization is by definition asymptom atic, AST, which includes use of active surveillance cultures and other laboratory techniques for identifying MOROs, sig nificantly increases detection of colonized patients in a facility. 11 ·
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21 -29 VRE and MOR gram-negative bacilli are often present only in the gastrointestinal tract and might not be routinely detected by clinical cultures. In addition to detecting the hidden reservoir, AST also increases the detection of MORO carriage, thus lessening the likelihood that carriers will be misclassified as having new nosocomial acquisition of an MORO. Although AST enables metrics to be substantially more accurate by reducing misclassification, it creates an up front need for financial resources and places an increased burden on the clinical laboratory; thus, appropriate planning is warranted, particularly in areas of low prevalence; 30 For tunately, estimates of the rate of recovery of MOROs from clinical cultures often parallel estimates derived from AST for acquisition of MRSA in the ICU. 25 According to one study, however, this is not the case for rates of acquisition of VRE in the ICU. 24 For VRE, and likely for MOR gram-negative bacilli, metrics based on AST provide better estimates of MDRO prevalence and rates of healthcare-associated acqui sition (hereafter healthcare acquisition), because asymptom atic colonization is very common.
Many aspects of an AST program will influence the re producibility and validity of the results. These include the choice of anatomic sites for specimen collection, which MDRO is measured, the testing and reporting method, and compliance with AST among eligible patients.
1 The sensitivity of commonly employed AST techniques ranges from 50% to 90%, and sensitivity varies depending on the bacteria detected and the method used.
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Healthcare facilities may or may not choose to conduct AST; 2 recent studies offer conflicting findings as to whether AST for MRSA, followed by measures to prevent transmission by identified carriers, can significantly reduce MRSA disease burden.
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Description of MORO Metrics
We have divided the recommended MORO metrics into 5 categories based on the purpose of the metrics: (1) tracking patients, (2) monitoring susceptibility patterns, ( 3) estimating infection burden, (3) estimating exposure burden, and (5) quantifying healthcare acquisition. For each category, we will discuss the recommended metrics and surveillance methods. The metrics and their definitions are summarized in Table 2 .
Tracking patients. The most basic, time-honored method for tracking MDROs is the line list, which is essentially an annotated case count. For each hospital unit or healthcare facility, the first MORO isolate recovered from a patient, re gardless of source of specimen, is added to a list. The line list is not a rate and has no denominator. It does not have a defined surveillance period because the list is continually updated. The line list is derived using data from clinical cul tures and AST, if available.
The line list has several uses. It is simple and could be the only essential metric for rare MDROs, such as vancomycin resistant S. aureus and some MDR gram-negative bacilli. For more common MDROs, such as MRSA, the line list provides identification of patients with a history of infection or col onization, for calculating prevalence or incidence rates. The line list can be used to trigger and follow outbreak investi gations for new or rapidly emerging MDROs. An increase in · the number of cases in a healthcare facility may signify a growing problem and may require the additional collection of data to confirm a rise in incidence or incidence density.
The essential elements of the line list include patient iden tification, source of specimen and date of first positive result, hospital location at time of specimen collection, date of ad mission, and date of last discharge from the healthcare facility. Operationally, the line list could be an electronic system that flags patients admitted to a facility for rapid identification and contact isolation if they have a history of MORO colo nization or infection. Classification of MDROs can be made as outlined in Table 1 .
Monitoring susceptibility patterns. A commonly used metric for cumulative susceptibility to antimicrobial agents is the antibiogram (ie, the proportion of isolates of a specific path ogen susceptible to a specified agent). 37 Historically, the main purpose of the antibiogram has been to provide guidance for antimicrobial prescribing practices; however, the antibiogram can also be used to monitor progress in assessing the pro portion of MDROs resistant to certain antibiotics of interest. Although this proportion is identified on the basis of clinical culture results without confirmation of infection, it is still useful in assessing resistance among isolates that can lead to infection. Nevertheless, the antibiogram might underestimate the resistance of isolates that definitively cause infection for some pathogens, such as MRSA 38 and MOR gram-negative bacilli. 39 Although antibiograms are easily constructed using common laboratory systems, they have the following disad vantages: ( 1) a decrease in the number of patients infected with an MDRO (and not the proportion of isolates suscep tible) is often the goal of intervention, and this goal may not be reflected in the proportion metric reported in the anti biogram; (2) many healthcare facilities only construct annual, facility-wide antibiograms, an approach that might not allow evaluation of a unit-specific intervention; (3) the percentage of isolates susceptible may change slowly in response to an intervention; and ( 4) the antibiogram might not translate well to rates of antibiotic resistant infection among patients with confirmed disease.
The Clinical and Laboratory Standards Institute ( CLSI) guideline document provides recommendations for how to construct an antibiogram. 37 We support the CLSI recom mendations that antibiograms be created only for species with at least 30 isolates tested, and they should include only isolates from clinical cultures and not isolates from AST. In outbreak situations, facilities might choose to create antibiograms for fewer than 30 isolates, to assess whether they have similar profiles. Only the first isolate recovered from a patient during a surveillance period should be included. Isolates that produce test results indicating intermediate resistant should not be classified as susceptible. The CLSI recommends constructing antibiograms at least annually; in some circumstances, facil ities might want to construct antibiograms monthly or quar terly, to monitor quickly changing susceptibility patterns. Concerns and further suggestions on the construction of antibiograms have been described elsewhere.
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Estimating infection burden. When monitoring an MORO, facilities should have some estimate of the overall burden of the MORO at their institution. One metric min imally influenced by variation in practices of clinical testing is the incidence of hospital-onset MDRO bacteremia. Blood samples for culture are routinely drawn in response to fever. Positive blood culture results are simple to identify, are highly likely to represent infection, and are a well-validated metric.
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In addition, this metric has been shown to decrease in re sponse to interventions to prevent MDRO infections in pub lished studies from institutions with high rates of MRSA
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and VRE 43 bacteremia.
We recommend that a proxy for MORO bacteremia be defined as a blood culture positive for an MORO, excluding those blood culture results obtained within 14 days after a previous episode of bacteremia due to the same MORO. We recommend the 14-day interval to differentiate between per sistent bacteremia and relapse or recurrent bacteremia. Ac cording to this surveillance definition (ie, proxy for MDRO bacteremia), a patient might have more than 1 episode of bacteremia in a surveillance period if the time from the last positive blood culture result to the next is at least 14 days. Two separate episodes of bacteremia should be counted, even if the 14-day interval spans 2 surveillance periods. We rec ommend using the 14-day interval to ensure that the second culture sample is obtained well after the median length of time needed to sterilize the bloodstream when treating bac teremia.44-46 Although using this proxy measure for blood stream infection may not always reflect true disease ( occa sionally an MRSA or VRE blood culture isolate may represent skin contamination), this metric has some demonstrated suc cess related to prevention of MDRO infection and has had some success as part of a national system used by the Health Protection Agency in the United Kingdom.
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Another metric that may be useful to healthcare facilities is the incidence of nosocomial, organism-specific infection, such as the incidence of MRSA infection. This metric would include a clinical evaluation of all specimens representing infection with an MORO as defined by the CDC.
1° Facilities might also want to monitor infections with specific organisms in specimens other than blood by calculating an organism specific, device-or procedure-associated incidence density. For example, institutions might want to consider a specific metric of infection burden when monitoring an increase of Acinetobacter baumannii pneumonia in ventilated patients, extended-spectrum /3-lactamase-producing K. pneumoniae infection in patients with indwelling urinary catheters, or MRSA surgical site infections in patients who recently un derwent coronary artery b yp ass graft procedures.
Estimating exposure burden. The metrics for exposure burden track the amount of exposure that patients in a health care facility have to patients who are either colonized or in fected with an MORO and who could potentially transmit the MORO to them. This colonization pressure is an inde pendent risk factor for healthcare acquisition of MRSA 48 and VRE, 49 and has been calculated in several ways in research studies. We recommend a simple approach that should help healthcare facilities gauge whether exposure levels are high and should potentially explain any ongoing transmission of MDROs. For MRSA colonization or infection in healthcare facilities where AST is not routinely performed, we recom mend calculating an overall prevalence based on clinical cul tures, including those from specimens from patients with MDRO isolates identified and those from specimens from patients with a history of colonization. Clinical cultures in clude all cultures of samples gathered to evaluate possible infection and not gathered as part of AST; for example, this includes culture of catheter tips to evaluate for infection. This metric is helpful for MRSA, in particular, because prevalence based on clinical cultures alone has been shown to be cor related with prevalence based on AST and clinical cultures. Nevertheless, prevalence based on clinical cultures alone sig nificantly underestimates the full reservoir and illuminates only the tip of the "resistance iceberg." 50 In healthcare facil ities where AST is conducted, this metric should also include patients with positive AST results. This metric will be espe cially useful for institutions that care for patients who do not seek health care outside of the institution's system; on the other hand, this metric will be more difficult to interpret for facilities that share patient populations.
Repeated point prevalence surveys can demonstrate de creased prevalence over time in response to active infection prevention and control interventions, as was shown in a large study of VRE by Ostrowsky et al. 51 Such surveys can be an important adjunct to ongoing, monthly surveillance, because they can be used in addition to recommended metrics and can help the staff of a healthcare facility gauge the magnitude by which clinical cultures alone underestimate prevalence at a given institution. The results of point prevalence surveys could help identify areas with high MORO endemicity where heightened surveillance or AST would be helpful. Rhame and Sudderth 52 proposed a mathematical model to estimate the incidence rate from prevalence surveys. Although evaluations of this formula have demonstrated that the prevalence of nosocomial infections is related to the incidence, 53 this does not replace the direct metric of incidence, and measurement of point prevalence is not recommended as a · routine practice.
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Another useful exposure burden estimate is admission prevalence. This metric allows healthcare facilities to identify the magnitude of importation of an MORO in the facility. It can also help identify whether importation is due to the read mission of recently discharged patients or to the transfer of patients from other healthcare facilities. A positive MORO test result from the emergency department should be counted in an admission prevalence, if the specimen is obtained while the patient is awaiting admission.
Quanti fying healthcare acquisition. Determining the rate of healthcare acquisition of MDROs is the outcome that al lows the most direct assessment of the effectiveness of pre vention programs. Healthcare acquisition is a term that in cludes not only environmental, patient-to-patient, and healthcare personnel-to-patient transmission but also de novo development of drug resistance, such as resistance due to antibiotic pressure. Virtually all new occurrences of MRSA or VRE colonization are the result of transmission, but an tibiotic pressure might influence the likelihood of transmis sion and could be an important factor in the development of infections with MDR gram-negative bacilli (eg, Entero bacter species with inducible cephalosporin resistance).
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The recommended metric for healthcare acquisition of most MOROs is the incidence rate based on clinical culture results. This metric applies to all hospitals but may under estimate or misclassify incident cases in the absence of AST. Nevertheless, in certain situations, such as MRSA coloniza tion or infection in ICUs, the incidence rate based on clinical culture results could be a reasonable proxy. 25 The usefulness of this metric for MOR gram-negative bacilli might vary de pending on the genus involved. 56 Patients with a history of MORO colonization or infection must be excluded from the numerator because their inclusion will artificially inflate the incidence rate. Similarly, one could consider removing these patients from the denominator, especially for areas of high prevalence, to prevent the artificial deflation of the incidence rate. However, we do not recommend this practice, because it is labor intensive and may not affect the assessment of trends within facilities.
Use of AST will identify the transmission ofMOROs better than use of clinical cultures alone, but even incidence rates based on both AST and clinical cultures are only an estimate of the rate of healthcare acquisition. AST will have its greatest impact in detecting the transmission of MOROs unlikely to be detected by clinical cultures alone, such as VRE. 24 If an incidence rate based on both clinical cultures and AST is used to demonstrate the acquisition of MOROs in a healthcare facility, it would be useful to show that a particular patient had a baseline negative AST result and then became colonized or infected during his or her hospital stay. 57 This type of assessment might be preferable for a research study or at an institution with sufficient staff to stratify by hospital area, where patients are or are not evaluated by AST. For the pur pose of routine MORO surveillance, we recommend defining a likely transmission event as an MORO-positive clinical cul ture or AST result for any patient who previously had no MORO colonization or infection on admission (because the patient either had no prior history of MORO colonization or infection, had no positive clinical or AST result during the first 3 calendar days of hospitalization, or had not been tested during the first 3 days of hospitalization).
Recommended metrics for specific MDROs. Table 3 lists the recommended metrics for MRSA, VRE, and MOR gram-neg ative bacilli. For vancomycin-resistant S. aureus, use of a line · list is sufficient, because this organism is extremely rare. Rec ommendations have been categorized as "basic" or "ad vanced." Those metrics labeled "basic" are routinely used as standard practice or are believed to be central to making a meaningful assessment of the impact of a prevention inter vention. Those metrics labeled "advanced" are of great benefit in certain hospital settings, and the context in which these advanced metrics are recommended is noted in the comments in Ta ble 3. All healthcare facilities should use the basic metrics in all circumstances; the use of the advanced metrics does not supplant the use of the basic ones. Several of the advanced metrics could be critically important to the assessment of MOROs, but they might not be applicable in all hospital settings. These categorizations are mostly expert opinions that are based common practices or interpretations of the em pirical evidence in the literature.
Other surveillance methods have been proposed to monitor quality of care. For example, determining the number of days between infections and using control charts could be useful in the context of quality improvement and could help to communicate nosocomial infection rates to hospital staff.
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These methods can be used in addition to our recom mendations.
The surveillance of MOROs requires the ongoing support of microbiology laboratory technicians, infection prevention and control professionals, information technology specialists, and healthcare facility administrators. Conventional methods for microbiological culture can result in a delay of up to 5 days before results are available. Rapid detection methods, such as culture with media containing chromogenic enzyme substrates, and molecular detection methods, such as poly merase chain reaction assays, are being increasingly used, although they are more expensive and have not been shown to improve overall patient safety. Healthcare facilities could choose one method over the other depending on their as sessment of the MORO. A number of documents are available for guidance on performing a risk assessment for MRSA infection.
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This document provides important insights into the need for future research. As noted previously, substantial deficien cies exist in the medical literature available. Additional con siderations for future research include determining strategies for decolonization, improving interfacility communication on MOROs and the infections they cause, and assessing what constitutes a patient at high risk of acquiring various MOROs (Table 4) .
Limitations. Healthcare facilities must be consistent with their use of surveillance methodology and metric definitions if comparison of data from different time periods in a hospital is desired. For example, once a healthcare facility introduces AST, comparison with the data from earlier time periods will require the appropriate handling of the AST results to make temporal comparisons valid. The majority of the recom mended metrics are neither stratified by risk factors nor val idated by an abundance of published studies. Therefore, these metrics are designed to be used by healthcare facilities to track changes over time and should not be used for inter facility comparison, for a number of reasons. First, it is dif ficult, if not impossible, to identify a gold standard for mea suring MORO infection and colonization in a healthcare setting, so metrics will differ because of variations in the processes used to collect data, in the patient population, and in specimen collection practices. Second, the metrics pro posed in this document include both direct and proxy metrics, and the validity of proxy metrics has not been well established. Third, a valid risk adjustment of these metrics has not been established in the scientific literature. Lastly, some of the met rics that we recommend were taken from studies ofMOROs in healthcare facilities with high rates of MORO-related dis ease, and therefore they might not be applicable to healthcare facilities with lower rates of MORO-related disease.
Limited data exist for some of our recommendations, par ticularly for metrics of MOR gram-negative bacilli. There is a paucity of data on the burden of MOROs in the pediatric population and for nonhospitalized patients; thus, little guid ance exists on the best metrics to use for these patient pop ulations. Most of the metrics presented here were created on the basis of experience in other healthcare facilities and on the basis of studies undertaken in adult acute care hospitals.
SUMMARY
The assessment of MORO infection and colonization should include the identification of known carriers, the detection of hospital-specific and healthcare-associated acquisition, an es timation of the burden of serious infection, an understanding of the reservoir affecting the transmission of MOROs, and an evaluation of the effect of intervention. Several strategies can be used to obtain data that aid in this assessment. We have defined and categorized the recommended metrics for each of these aspects of measuring MORO infection and col onization, for use by healthcare facilities.
